Patent details

EP2943185 Title: SUSTAINED RELEASE FORMULATIONS OF LORAZEPAM

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
EP2943185
WO Application Number:
US2014010854
Type:
European Patent Granted for NL
Status:
Patent in Force
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP14702977.1
WO Publication Number:
WO2014110245
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
United States of America (US)
Publications:

Dates

Filing date:
09/01/2014
Grant date:
18/11/2020
EP Publication Date:
18/11/2015
WO Publication Date:
17/07/2014
Claims Translations Received Date:
Claims Translation B1 Received Date:
10/02/2021
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
18/11/2020
EP B1 Publication Date:
18/11/2020
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
08/01/2034
Lapsed By Expiration Date:
Patent Validated Date:
05/03/2021
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
10/02/2021
 
 

 

Name:
Edgemont Pharmaceuticals, LLC Liquidating Trust
Address:
1037 Raymond Blvd., Suite 1520, 07102, Newark, NJ, United States of America (US)

Historical Applicant/holder

From:
18/11/2020
To:
10/02/2021

 

Name:
Edgemont Pharmaceuticals LLC
Address:
1250 Capital of Texas Hwy South Building 3 Suite 400, Austin, Texas 78746, United States of America (US)

Agent

Name:
J.M.H. Duyver lic.
From:
04/03/2021
Address:
Gevers Patents De Kleetlaan 7A, B-1831, Diegem, Belgium (BE)
To:

Inventor

1

Name:
SALTEL, Douglas A.
Address:
Austin, Texas 78746, United States of America (US)

2

Name:
VACHON, Michael
Address:
Austin, Texas 78746, United States of America (US)

Priority

1

Priority Patent Number:
201361762833 P
Priority Date:
08/02/2013
Priority Country:
United States of America (US)

2

Priority Patent Number:
201361750797 P
Priority Date:
09/01/2013
Priority Country:
United States of America (US)

Classification

IPC or IDT classification:
A61K 9/16; A61K 9/50; A61K 31/5513; A61P 25/22; A61P 25/24;

Publication

Bulletin

1

Bulletin Heading:
CO
Journal edition number:
10/21
Publication date:
10/03/2021
Description:
Changes in the Netherlands Patent Register

2

Bulletin Heading:
EP3
Journal edition number:
10/21
Publication date:
10/03/2021
Description:
European patents granted for the Netherlands in which a translation was filed ex Article 52 par. 1 of the NL Patent Law 1995

3

Bulletin Heading:
EP2
Journal edition number:
47/20
Publication date:
18/11/2020
Description:
European patents granted for the Netherlands

European Patent Bulletin

Issue number:
202047
Publication date:
18/11/2020
Description:
Grant (B1)

Deed

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC202100438A
Date Registered:
10/02/2021
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
J.M.H. Duyver lic.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
Edgemont Pharmaceuticals, LLC Liquidating Trust
Address:
1037 Raymond Blvd., Suite 1520, 07102, Newark, NJ, United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
31/01/2026
Annual Fee Number:
13
Annual Fee Amount:
700 Euro
Last Annual Payment Date:
15/01/2025
Last Annual Fee Paid Number:
12
Last Annual Fee Paid Amount:
600 Euro
Payer:
Computer Patent Annuities Limited (CPA)
Filing date Document type Document Description Number of pages File Type
04/03/2021 Outgoing Correspondence Letter no formal defects 1 PDF /0/1/0/3/2/0800623010/docs/ep14702977.1_1_398001l271.pdf
10/02/2021 Claims First filed claims 4 PDF /0/1/0/3/2/0800623010/docs/ep14702977.1_0_claims20210210141620148.pdf